FILE PHOTO: Vials of the Pfizer-BioNTech vaccine are pictured in a vaccination centre in Geneva, Switzerland, February 3, 2021. REUTERS/Denis Balibouse/File Photo | Photo Credit: DENIS BALIBOUSE
India is in talks to buy 50 million doses of Pfizer Inc and German partner BioNTech SE’s Covid-19 vaccine, the Wall Street Journal reportedon Wednesday, citing people familiar with the matter.
Pfizer and the Indian health ministry did not immediately respond to Reuters request for comments. The drugmaker has not yet sought permission for use of its vaccine in India.
The country, which rolled out one of the world's largest vaccination drives earlier this year, has been relying heavily on the AstraZeneca vaccine produced by the Serum Institute of India and a home-grown shot produced by Bharat Biotech.
Also read: J&J single-dose Covid-19 vaccine gets EUA in India
Authorities are also in an advanced stage of negotiations with Johnson & Johnson, which has a deal with India-based Biological E. Ltd, to manufacture as many as 600 million doses, starting as soon as this month, the Journal reported.
Last week, the country approved J&J's one-shot vaccine for emergency use, adding to the vaccines from AstraZeneca, Bharat Biotech, Russia’s Gamaleya Institute and Moderna, that have been granted such approval.
Published on August 12, 2021
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.